Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: Outcomes from a phase IIIB expanded access program

Pasi A. Jänne, Antoinette J. Wozniak, Chandra P. Belani, Mary Louise Keohan, Helen J. Ross, Jonathan A. Polikoff, David M. Mintzer, Zhishen Ye, Matthew J. Monberg, Coleman K. Obasaju

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

BACKGROUND: In a randomized phase III trial, pemetrexed plus cisplatin was associated with improved survival compared with cisplatin alone for patients with malignant pleural mesothelioma (MPM). However, there are limited data available on the efficacy of these and other chemotherapy regimens in patients who have received previous systemic chemotherapy. To gather additional efficacy and safety data of pemetrexed/cisplatin and pemetrexed alone in previously treated patients, we examined patients treated on the Eli Lilly and Company expanded access program (EAP). PATIENTS AND METHODS: Patients with malignant mesothelioma were enrolled in this trial. Of 1056 patients receiving at least one dose of the study drug, 187 (17.7%) were previously treated patients with MPM. Patients were treated every 21 days with pemetrexed 500 mg/m alone (n = 91) or in combination with cisplatin 75 mg/m (n = 96) for a maximum of six cycles. All patients received folic acid and vitamin B12 supplementation and steroid prophylaxis. Serious adverse events (SAEs) were reported by investigators and compiled in a pharmaco-vigilance database for all patients enrolled in the EAP. RESULTS: Median age of the previously treated pleural mesothelioma subset was 66 years (range, 27-87 years). Based on 153 evaluable patients (a subset of the larger intent-to-treat population of 187), the overall response rate was 32.5% for pemetrexed and cisplatin and 5.5% for pemetrexed alone. The disease control rate (response rate + stable disease) was 68.7% for pemetrexed and cisplatin and 46.6% for pemetrexed alone. Median survival was 7.6 months for pemetrexed plus cisplatin (67% censored) and 4.1 months for pemetrexed alone (55% censored). The most commonly reported serious adverse events in the overall EAP irrespective of causality were dehydration (7.2%), nausea (5.2%), vomiting (4.9%), dyspnea (3.8%), and pulmonary embolism (2.4%). CONCLUSIONS: The data from this EAP study suggest that patients with previously treated MPM can benefit from treatment with pemetrexed alone or in combination with cisplatin. The treatment is associated with acceptable toxicity.

Original languageEnglish (US)
Pages (from-to)506-512
Number of pages7
JournalJournal of Thoracic Oncology
Volume1
Issue number6
StatePublished - Jul 1 2006

Fingerprint

Pemetrexed
Cisplatin
Malignant Mesothelioma
Drug Therapy
Survival
Mesothelioma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Jänne, Pasi A. ; Wozniak, Antoinette J. ; Belani, Chandra P. ; Keohan, Mary Louise ; Ross, Helen J. ; Polikoff, Jonathan A. ; Mintzer, David M. ; Ye, Zhishen ; Monberg, Matthew J. ; Obasaju, Coleman K. / Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma : Outcomes from a phase IIIB expanded access program. In: Journal of Thoracic Oncology. 2006 ; Vol. 1, No. 6. pp. 506-512.
@article{b458ab393c07490bb99d2a5185841ce3,
title = "Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: Outcomes from a phase IIIB expanded access program",
abstract = "BACKGROUND: In a randomized phase III trial, pemetrexed plus cisplatin was associated with improved survival compared with cisplatin alone for patients with malignant pleural mesothelioma (MPM). However, there are limited data available on the efficacy of these and other chemotherapy regimens in patients who have received previous systemic chemotherapy. To gather additional efficacy and safety data of pemetrexed/cisplatin and pemetrexed alone in previously treated patients, we examined patients treated on the Eli Lilly and Company expanded access program (EAP). PATIENTS AND METHODS: Patients with malignant mesothelioma were enrolled in this trial. Of 1056 patients receiving at least one dose of the study drug, 187 (17.7{\%}) were previously treated patients with MPM. Patients were treated every 21 days with pemetrexed 500 mg/m alone (n = 91) or in combination with cisplatin 75 mg/m (n = 96) for a maximum of six cycles. All patients received folic acid and vitamin B12 supplementation and steroid prophylaxis. Serious adverse events (SAEs) were reported by investigators and compiled in a pharmaco-vigilance database for all patients enrolled in the EAP. RESULTS: Median age of the previously treated pleural mesothelioma subset was 66 years (range, 27-87 years). Based on 153 evaluable patients (a subset of the larger intent-to-treat population of 187), the overall response rate was 32.5{\%} for pemetrexed and cisplatin and 5.5{\%} for pemetrexed alone. The disease control rate (response rate + stable disease) was 68.7{\%} for pemetrexed and cisplatin and 46.6{\%} for pemetrexed alone. Median survival was 7.6 months for pemetrexed plus cisplatin (67{\%} censored) and 4.1 months for pemetrexed alone (55{\%} censored). The most commonly reported serious adverse events in the overall EAP irrespective of causality were dehydration (7.2{\%}), nausea (5.2{\%}), vomiting (4.9{\%}), dyspnea (3.8{\%}), and pulmonary embolism (2.4{\%}). CONCLUSIONS: The data from this EAP study suggest that patients with previously treated MPM can benefit from treatment with pemetrexed alone or in combination with cisplatin. The treatment is associated with acceptable toxicity.",
author = "J{\"a}nne, {Pasi A.} and Wozniak, {Antoinette J.} and Belani, {Chandra P.} and Keohan, {Mary Louise} and Ross, {Helen J.} and Polikoff, {Jonathan A.} and Mintzer, {David M.} and Zhishen Ye and Monberg, {Matthew J.} and Obasaju, {Coleman K.}",
year = "2006",
month = "7",
day = "1",
language = "English (US)",
volume = "1",
pages = "506--512",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

Jänne, PA, Wozniak, AJ, Belani, CP, Keohan, ML, Ross, HJ, Polikoff, JA, Mintzer, DM, Ye, Z, Monberg, MJ & Obasaju, CK 2006, 'Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: Outcomes from a phase IIIB expanded access program', Journal of Thoracic Oncology, vol. 1, no. 6, pp. 506-512.

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma : Outcomes from a phase IIIB expanded access program. / Jänne, Pasi A.; Wozniak, Antoinette J.; Belani, Chandra P.; Keohan, Mary Louise; Ross, Helen J.; Polikoff, Jonathan A.; Mintzer, David M.; Ye, Zhishen; Monberg, Matthew J.; Obasaju, Coleman K.

In: Journal of Thoracic Oncology, Vol. 1, No. 6, 01.07.2006, p. 506-512.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma

T2 - Outcomes from a phase IIIB expanded access program

AU - Jänne, Pasi A.

AU - Wozniak, Antoinette J.

AU - Belani, Chandra P.

AU - Keohan, Mary Louise

AU - Ross, Helen J.

AU - Polikoff, Jonathan A.

AU - Mintzer, David M.

AU - Ye, Zhishen

AU - Monberg, Matthew J.

AU - Obasaju, Coleman K.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - BACKGROUND: In a randomized phase III trial, pemetrexed plus cisplatin was associated with improved survival compared with cisplatin alone for patients with malignant pleural mesothelioma (MPM). However, there are limited data available on the efficacy of these and other chemotherapy regimens in patients who have received previous systemic chemotherapy. To gather additional efficacy and safety data of pemetrexed/cisplatin and pemetrexed alone in previously treated patients, we examined patients treated on the Eli Lilly and Company expanded access program (EAP). PATIENTS AND METHODS: Patients with malignant mesothelioma were enrolled in this trial. Of 1056 patients receiving at least one dose of the study drug, 187 (17.7%) were previously treated patients with MPM. Patients were treated every 21 days with pemetrexed 500 mg/m alone (n = 91) or in combination with cisplatin 75 mg/m (n = 96) for a maximum of six cycles. All patients received folic acid and vitamin B12 supplementation and steroid prophylaxis. Serious adverse events (SAEs) were reported by investigators and compiled in a pharmaco-vigilance database for all patients enrolled in the EAP. RESULTS: Median age of the previously treated pleural mesothelioma subset was 66 years (range, 27-87 years). Based on 153 evaluable patients (a subset of the larger intent-to-treat population of 187), the overall response rate was 32.5% for pemetrexed and cisplatin and 5.5% for pemetrexed alone. The disease control rate (response rate + stable disease) was 68.7% for pemetrexed and cisplatin and 46.6% for pemetrexed alone. Median survival was 7.6 months for pemetrexed plus cisplatin (67% censored) and 4.1 months for pemetrexed alone (55% censored). The most commonly reported serious adverse events in the overall EAP irrespective of causality were dehydration (7.2%), nausea (5.2%), vomiting (4.9%), dyspnea (3.8%), and pulmonary embolism (2.4%). CONCLUSIONS: The data from this EAP study suggest that patients with previously treated MPM can benefit from treatment with pemetrexed alone or in combination with cisplatin. The treatment is associated with acceptable toxicity.

AB - BACKGROUND: In a randomized phase III trial, pemetrexed plus cisplatin was associated with improved survival compared with cisplatin alone for patients with malignant pleural mesothelioma (MPM). However, there are limited data available on the efficacy of these and other chemotherapy regimens in patients who have received previous systemic chemotherapy. To gather additional efficacy and safety data of pemetrexed/cisplatin and pemetrexed alone in previously treated patients, we examined patients treated on the Eli Lilly and Company expanded access program (EAP). PATIENTS AND METHODS: Patients with malignant mesothelioma were enrolled in this trial. Of 1056 patients receiving at least one dose of the study drug, 187 (17.7%) were previously treated patients with MPM. Patients were treated every 21 days with pemetrexed 500 mg/m alone (n = 91) or in combination with cisplatin 75 mg/m (n = 96) for a maximum of six cycles. All patients received folic acid and vitamin B12 supplementation and steroid prophylaxis. Serious adverse events (SAEs) were reported by investigators and compiled in a pharmaco-vigilance database for all patients enrolled in the EAP. RESULTS: Median age of the previously treated pleural mesothelioma subset was 66 years (range, 27-87 years). Based on 153 evaluable patients (a subset of the larger intent-to-treat population of 187), the overall response rate was 32.5% for pemetrexed and cisplatin and 5.5% for pemetrexed alone. The disease control rate (response rate + stable disease) was 68.7% for pemetrexed and cisplatin and 46.6% for pemetrexed alone. Median survival was 7.6 months for pemetrexed plus cisplatin (67% censored) and 4.1 months for pemetrexed alone (55% censored). The most commonly reported serious adverse events in the overall EAP irrespective of causality were dehydration (7.2%), nausea (5.2%), vomiting (4.9%), dyspnea (3.8%), and pulmonary embolism (2.4%). CONCLUSIONS: The data from this EAP study suggest that patients with previously treated MPM can benefit from treatment with pemetrexed alone or in combination with cisplatin. The treatment is associated with acceptable toxicity.

UR - http://www.scopus.com/inward/record.url?scp=33846099270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846099270&partnerID=8YFLogxK

M3 - Article

C2 - 17409909

AN - SCOPUS:33846099270

VL - 1

SP - 506

EP - 512

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -